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Background: [18F]AV1451 is a commonly used radiotracer for imaging tau deposits
in Alzheimer’s disease (AD) and related non-AD tauopathies. Existing radiosyntheses
of [18F]AV1451 require complex purifications to provide doses suitable for use in
clinical imaging studies. To address this issue, we have modified the synthesis of
[18F]AV1451 to use only 0.5 mg precursor, optimized the Boc-deprotection step and
developed a simplified method for HPLC purification of the radiotracer.
Results: An optimized [18F]AV1451 synthesis using a TRACERLab FXFN module led to
high radiochemical yield (202 ± 57 mCi per synthesis) and doses with excellent
radiochemical purity (98 ± 1%) and good specific activity (2521 ± 623 Ci/mmol).
Conclusion: An updated and operationally simple synthesis of [18F]AV1451 has been
developed that is fully automated and prepares radiotracer doses suitable for use in
clinical tau PET studies.
Keywords: Tau imaging, Brain PET, [18F]T807, Flortaucipir F18, Fluorine-18
radiochemistry, Automated radiosynthesisBackground
Neurodegenerative disorders are frequently associated with at least one misaggregated
protein (Sweeney et al. 2017). Historically, physicians have attempted to diagnose such
disorders based upon clinical symptoms, with definitive diagnosis finalized by patholo-
gists during post-mortem examination. In recent years however, there has been consid-
erable effort to move diagnostic strategy from clinical detection of signs and symptoms
of mid-stage disease, to early detection of pharmacological biomarkers of pre-
symptomatic disease (for a recent review, see: Ahmed et al. 2014). This is expected to
improve patient prognosis by enabling initiation of treatment prior to loss of neuronal
function (and associated cognitive decline), and can be used to support development
of disease modifying therapeutics. Diagnostic tests that allow confirmation of abnormal
protein deposits in pre-symptomatic disease are therefore of the utmost importance.
Tau proteins are commonly found in neurons where they promote assembly and
stabilization of microtubules (for a recent review of the role of tau in physiology and
pathology, see: Wang and Mandelkow 2016). However, in Alzheimer’s disease (AD)
dysfunction of enzymes that are responsible for phosphorylating tau, such as glycogen
synthase kinase-3, gives rise to a hyperphosphorylated version of the protein that
aggregates and forms insoluble intracellular tau neurofibrillary tangles (NFTs)The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International
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and the neuronal damage/cognitive decline associated with the later stages of AD
(Haroutian et al. 2007). Given this correlation, as well as the number of tau-based therap-
ies being developed (Boutajangout et al. 2011; Panza et al. 2016), a tau PET imaging agent
would allow for the selection of tau-positive AD patients for enrollment in clinical trials
of such experimental treatments, and provide a means to monitor response to therapy. In
addition to AD, misaggregated tau is implicated in a range of other tauopathies (e.g.
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and tau variants
of frontotemporal dementia (FTD)), and a tau radiotracer can be expected to have similar
impact in all of these disorders (for reviews of the role of tau in AD and non-AD
tauopathies, see: Iqbal et al. 2005, 2010, 2016).
Many different tau radiotracers have been reported to date (for recent reviews, see:
Ariza et al. 2015; James et al. 2015; Villemagne et al. 2015; Watanabe et al. 2015; Kolb
and Andrés, 2017; Hall et al. 2017; Saint-Aubert et al. 2017). Of these, [18F]AV1451 (7-
(6-[18F]fluoropyridin-3yl)-5H-pyrido[4,3-b]indole, flortaucipir F18, [18F]T807) devel-
oped by Siemens Molecular Imaging and Biomarker Research (Xia et al. 2013), and
subsequently licensed to Eli Lilly / Avid Radiopharmaceuticals, has been among the
most utilized in clinical tau PET imaging to date. It has been used to image patients
with AD (see, for example: Schwarz et al. 2016), non-AD tauopathies (Marquié et al.
2017) including PSP (Passamonti et al. 2017; Smith et al. 2017) and CBD (McMillan
et al. 2016), and non-tauopathies such as dementia with Lewy bodies (Gomperts et al.
2016). Methods for kinetic modeling of [18F]AV1451 have been developed (Shcherbinin
et al. 2016; Baker et al. 2017; Barret et al. 2017; Hahn et al. 2017), and studies have also
been conducted to establish biomarker endpoints (Jack et al. 2017) and human
dosimetry (Choi et al. 2016). As a cautionary side note, all of this work has also
identified potential off-target binding of [18F]AV1451 in brain areas such as the
basal ganglia. Such binding may be due to specific binding of the radiotracer to
monoamine oxidase A (MAO-A) (Vermeiren et al. 2015) or neuromelanin (Hansen
et al. 2016), and should be accounted for during image analysis. Nevertheless,
[18F]AV1451 PET has been used to identify distinct cortical spreading patterns of
tau pathology, aiding in our understanding of how tau distribution propagates
across the brain (Sepulcre et al. 2016) and to develop image-based tau staging
(Cho et al. 2016; Wang et al. 2016).
In connection with an NIH-funded project developing imaging biomarkers for
dementia with Lewy body patients, we had cause to make [18F]AV1451 available
for clinical use. Reflecting its widespread use, several different syntheses of
[18F]AV1451 suitable for clinical use have been reported. Shoup and Gao both re-
ported syntheses of [18F]AV1451 from N-Boc-protected nitro precursor (Shoup
et al. 2013; Gao et al. 2015), which eliminated the need for the reduction of the
nitro precursor prior to purification that the original report required to facilitate
purification of [18F]AV1451 (Xia et al. 2013). More recently, Holt et al. reported
18F-fluorination of N-Boc-protected trimethylammonium precursor by microwave
irradiation (Holt et al. 2016). Given the commercial availability of the N-Boc-nitro
precursor 1, and its amenability to use in a standard radiosynthesis module that
employs thermal heating, it was our choice for further development of a radio-
synthesis of [18F]AV1451 2 for routine clinical production.
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point, we were unsatisfied with various aspects of these reports, including: i) ambiguity
surrounding deprotection of Boc-protected [18F]AV1451, since both Shoup and Gao
describe the Boc group being removed concomitantly with fluorination (through either
thermal promotion or due to the basic reaction conditions) while Holt includes a separ-
ate acid-mediated deprotection (Shoup et al. 2013; Gao et al. 2015; Holt et al. 2016); ii)
the need for solid-phase extraction (SPE) purification steps both pre- and post-semi-
preparative HPLC purification, which necessitates a reconfiguration of the synthesis
module in the Shoup method; iii) the Gao method used a purpose built set-up which
could complicate compliance with current Good Manufacturing Practice (cGMP), and
the literature report contained none of the quality control and release data required to
determine if the procedure was compliant with the US Pharmacopeia; and iv) the use
of an MeCN-containing mobile phase in the Gao method (our laboratory has made
applying green methods when possible a priority to reduce environmental impact and
risk associated with class 2 solvents such as MeCN (Stewart et al. 2015), and simplify
quality control (QC) testing since eliminating such solvents reduces residual solvent
analysis to an annual QC test). To address these issues, we have undertaken a de-
tailed investigation of the radiosynthesis of [18F]AV1451, and herein report insights
into the N-Boc deprotection and a new operationally simple, greener method for
the radiosynthesis and purification of the radiotracer that uses a commercial syn-
thesis module without reconfiguration, and does not utilize any class 2 solvents in
the synthesis or purification.Methods
Materials for synthesis and analysis
Unless otherwise stated, reagents and solvents were commercially available and used
without further purification: N-Boc-protected nitro-precursor (Part No. NPPI-95-
0010C) and authentic AV1451 reference standard (Part No. FPPI-95-0002A) were
purchased from Huayi Isotopes/NucMedCor. Ethanol (200 proof, USP) was purchased
from Decon Laboratories, Inc. Sodium chloride 0.9%, USP and sterile water for
injection, USP were sourced from Hospira. Other synthesis components were obtained
as follows: Sterile vials were obtained from Hollister-Stier; Millex filters were from
Millipore; QMA-light and Oasis HLB 1 cc cartridges were purchased from Waters.
Prior to use QMA cartridges were conditioned with ethanol (10 mL), 0.5 M NaHCO3
(10 mL) and sterile water (10 mL), while HLB cartridges were conditioned with ethanol
(10 mL) and sterile water (10 mL).Radiosynthesis
The synthesis of [18F]AV1451 (Scheme 1) was fully-automated using a General Electric
(GE) TRACERLab FXFN synthesis module loaded as follows: V1: 500 μL 7 mg/mL
K2CO3 in water; V2: 1000 μL 15 mg/mL kryptofix-2.2.2 (K2.2.2) in ethanol; V3: 0.5 mg
precursor (N-Boc nitro) in 500 μL DMSO; V6: 3000 μL semi-preparative HPLC Buffer
(see below); V7: 6.5 mL buffered saline; V8: 500 μL ethanol; V9: 10 mL water; Dilution
flask: 50 mL water; product vial 3 mL buffered saline. [18F]Fluoride (~1400 mCi) was
produced via the 18O(p,n)18F nuclear reaction with a GE PETtrace cyclotron equipped
Scheme 1 Radiosynthesis of [18F]AV1451 (2)
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[18O]H2O to the synthesis module and trapped on a QMA-Light sep-pak cartridge to
remove [18O]H2O. [
18F]Fluoride was then eluted into the reaction vessel with potas-
sium carbonate (3.5 mg in 500 μL of water). The solution of K2.2.2 (15 mg in 1 mL of
ethanol) was added to the reaction vessel, and the [18F]fluoride was azeotropically dried
by heating the reaction vessel to 100 °C and drawing full vacuum for 6 min. After this
time, the reaction vessel was subjected to both an argon stream and a simultaneous
vacuum draw for 9 min at 100 °C. The solution of AV1451 N-Boc nitro-precursor in
DMSO (0.5 mg in 500 μL) was added to the dried [18F]fluoride, and was heated to
130 °C with stirring for 10 min. Subsequently, the reaction mixture was cooled to
50 °C, diluted with HPLC mobile phase (3 mL), and purified by semi-preparative
HPLC (column: Phenomenex Gemini NX C18, 5 micron, 10x250 mm; mobile phase: 40%
Ethanol 10 mM Na2HPO4 pH: 9.3 ± 0.2; flow rate: 3 mL/min; UV: 254 nm; and a typical
semi-preparative trace, Fig. 1). The product peak (tR = 21–22 min) was collected into the
dilution flask where it was concomitantly diluted with 50 mL of sterile water. The result-
ing solution was passed through an Oasis HLB cartridge, which was then washed with
10 mL of sterile water. [18F]AV1451 was eluted with 0.5 mL of EtOH (USP for injection)
and collected in the Tracerlab FXFN product vial, containg 3 mL of saline (USP). The Sep-
Pak was washed with 6.5 mL of saline to bring the final formulation volume to 10 mL.Fig. 1 Typical semi-preparative HPLC trace from synthesis of [18F]AV1451
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through a 0.22 μm sterile filter and submitted for QC testing as outlined in the Quality
Control section.Quality control
Quality control testing of [18F]AV1451 doses was conducted according to the guide-
lines outlined in the U.S. Pharmacopeia and as described below. Testing included
visual inspection, pH, residual K2.2.2, chemical purity and radiochemical purity (RCP),
specific activity (SA), radionuclidic identity, sterile filter integrity, bacterial endotoxin
analysis, and sterility testing. Results for four process verification batches are reported
in Table 1.Visual inspection
Doses were visually examined and needed to be clear, colorless and free of particulate
matter.Dose pH
The pH of the [18F]AV1451 doses was analyzed by applying a small amount of the dose
to pH-indicator strips and determined by visual comparison to the scale provided. Dose
pH was required to be between 4.5 and 7.5.Residual K2.2.2
Residual K2.2.2 levels in [
18F]AV1451 doses were analyzed using the established spot test
(Scott and Kilbourn 2007). Strips of plastic-backed silica gel TLC plates saturated with
iodoplatinate reagent were spotted with water (negative control), 50 μg/mL K2.2.2 stand-
ard (positive control) and with the [18F]AV1451 dose. If K2.2.2 was present in a sample,
a blue–black spot appeared. Spots for the three samples were compared and a visual
determination of residual K2.2.2 in the dose was made; ≤50 μg/mL was acceptable.Table 1 QC Data for Process Verification Batches of [18F]AV1451
QC Test Release Criteria Batch 1 Batch 2 Batch 3 Batch 4
Visual inspection Clear, colorless, free of particulates Pass Pass Pass Pass
pH 4.5-7.5 5.0 5.0 5.0 5.0
Radiochemical Yield (mCi) >10 mCi 170 140 231 266
Radioactivity Conc. >10 mCi/10 mL 34 28 46 53
AV1451 Conc. ≤5.0 μg/mL 2.5 2.0 3.5 2.5
SA (Ci/mmol) N/A 1,789 3,228 2,788 2,278
RCP (%) >90% 98 97 98 100
Radiochemical Identity RRTa =0.9-1.1 1.0 1.0 1.0 1.0
Radionuclidic Identity t1/2 = 105-115 min 107 107 110 109
Residual K2.2.2 ≤50 μg/mL ≤50 ≤50 ≤50 ≤50
Filter Integrity >44 psi 51 50 50 51
Bacterial Endotoxins <17.5 EU/mLb <2.00 <2.00 <2.00 <2.00
Sterility Sterile Sterile Sterile Sterile Sterile
aRRT = Relative retention time (tR [
18F]AV1451 / tR of [
19F]AV1451 standard); b EU = Endotoxin units
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Chemical and radiochemical purities/identities are analyzed using a Shimadzu LC2010
HPLC equipped with a radioactivity detector and an ultraviolet (UV) detector (column:
Gemini NX C18 5 micron 4.6x250 mm; mobile phase: 40% Ethanol 10 mM Na2HPO4
pH: 9.3 ± 0.2; flow rate: 1 mL/min; UV: 254 nm). A representative analytical HPLC
trace is shown in Fig. 2 ([18F]AV1451 tR = 13.2 min) and with an overlay of the UV
trace of the reference standard in Fig. 3. Radiochemical purity for doses must be >90%,
and identity was confirmed by comparing the retention time of the radiolabeled
product with that of the corresponding unlabeled reference standard.Radionuclidic Identity
Radionuclidic identity was confirmed by determining the half-life of [18F]AV1451 doses
and comparing it to the known half-life of fluorine-18 (109.77 min). Activities were
measured using a Capintec dose calibrator and half-life was calculated using Eq. (1).
Calculated half-life must be 105–115 min.
T1=2 ¼ ‐ ln2 Time Difference= ln ending activity=starting activityð Þð Þð Þ ð1Þ
Sterile filter integrity (Bubble Point) test
Sterile filters from doses (with needle still attached) were connected to a nitrogen
supply via a regulator. The needle is then submerged in water and the nitrogen
pressure gradually increased. If the pressure was raised above the filter acceptance
pressure (44 psi) without seeing a stream of bubbles, the filter was considered intact.Bacterial endotoxins
Endotoxin content in [18F]AV1451 doses was analyzed by a Charles River Laboratories
EndoSafe® Portable Testing System and according to the US Pharmacopeia. Doses must
contain ≤175 Endotoxin Units (EU), or ≤17.5 EU/mL.Fig. 2 [18F]AV1451 QC HPLC traces (UV above, Radioactivity below) are representative of those observed
Fig. 3 Typical Analytical HPLC trace of [18F]AV1451: gamma detection trace with overlay of UV trace of
genuine standard (Standard UV trace above, Product Radioactivity trace below)
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Culture tubes of fluid thioglycolate media (FTM) and tryptic soy broth (TSB) were
inoculated with samples of [18F]AV1451 and incubated (along with positive and nega-
tive controls) for 14 days. FTM was used to test for anaerobes, aerobes and microaero-
philes while TSB was used to test for non-fastidious and fastidious microorganisms.
Culture tubes were visually inspected on the 3rd, 7th and 14th days of the test period
and compared to the positive and negative standards. Positive standards needed to
show growth (turbidity) in the tubes, and [18F]AV1451 doses/negative controls had to
show no culture growth after 14 days to be indicative of sterility.
Results and discussion
[18F]AV1451 2 features a carbazole scaffold appended with a 2-fluoropyridine moiety,
which is the site of radiofluorination. The corresponding nitro-precursor 1 is an at-
tractive starting point to synthesize the radiotracer because of its commercial availabil-
ity, but is less often used than its trimethylammonium counterpart due to two major
issues: i) poor solubility of the precursor in polar aprotic solvents used for SNAr chem-
istry (displacement of -NO2 with -
18F), and ii) difficulties in separation of precursor
and product using semi-preparative HPLC.
Issues with solubility of the nitro-precursor have been partially resolved by N-Boc
protection of the carbazole nitrogen, which improves solubility by increasing the lipo-
philicity of the molecule. Literature reports are unclear as to whether N-Boc protection
improves radiochemical conversion or if increased yields are due to the solubility
afforded (Shoup et al. 2013; Gao et al. 2015). Ambiguity also surrounds the deprotec-
tion of N-Boc-protected [18F]AV1451 in the literature: Shoup and Gao describe the N-
Boc group being removed concomitantly with fluorination through either thermal pro-
motion or due to the basic reaction conditions (Shoup et al. 2013; Gao et al. 2015),
while Holt and co-workers add HCl following fluorination to deprotect in a separate
deprotection step (Holt et al. 2016). We were also uncertain whether the acidic HPLC
buffer specified in the report by Shoup might also be contributing to deprotection.
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of AV1451 versus predicted and literature values of analogues to determine why
AV1451 would behave differently than a typical carbazole or indole (pKa values sourced
either from the literature and/or predicted with JChem (https://epoch.uky.edu/ace/
public/pKa.jsp) or ADMET Predictor 7.2 (courtesy of Adam C. Lee, PhD at Dupont)
are summarized in Fig. 4). We found that γ-carbolines (Angulo et al. 1997) are more
acidic than corresponding carbazole (Bordwell et al. 1981; Maran et al. 1991), azain-
dole (Adler and Albert 1960) and indole (Bordwell et al. 1981; Maran et al. 1991) and
reasoned this observed change in electronics could explain why thermal removal of
an N-Boc protecting group is possible with [18F]AV1451. To experimentally deter-
mine the extent of thermal deprotection, reactions were run (Scheme 2) and analyzed
by HPLC (Fig. 5). N-Boc nitro precursor 1 was dissolved in DMSO and heated at
130 °C. Aliquots were removed at 1, 5 and 10 minutes and analyzed by HPLC. Within
1 min, the ratio of N-Boc precursor 1 (tR = 20.3 min) : deprotected precursor 3 (tR = 14.7 mi-
nutes) was 95 : 5 (Fig. 5). Greater conversion was observed at 5 min (1 : 3 = 52 : 48), and at
10 min the majority of N-Boc precursor 1 was thermally deprotected (1 : 3 = 22 : 78). These
results confirmed the feasibility of thermal deprotection, and that basic or acidic
conditions are not required for the removal of the N-Boc protecting group during
the synthesis of [18F]AV1451.
To study the radiofluorination reaction, [18F]KF/K2CO3/K2.2.2 was prepared as a stock
solution in DMSO and reactions with the N-Boc-protected nitro precursor were carried
out manually. Two products were observed by radio-TLC and radio-HPLC (Scheme 2
and Fig. 6), corresponding to the [18F]N-Boc intermediate 4 (tR = 21–22 min) and
[18F]AV1451 2 (tR = 12 – 13 min). Aliquots taken at 1 min demonstrated that the inter-
mediate was the major radiolabeled product and that the precursor was still N-Boc pro-
tected. The RCC of the intermediate at this time was 43.4% with only 5.5% RCC to
[18F]AV1451. At 5 min the RCC to intermediate 4 and [18F]AV1451 2 were 47% and
23%, respectively. Finally, after a 10 min reaction at 130 °C, thermal deprotection of the
Boc group resulted in 47% RCC to [18F]AV1451 (23% of the activity balance remained
as intermediate 4). Interestingly, we noted that conversion of [18F]KF to intermediate 4
(or product 2) did not appreciably increase from 5 to 10 min.Fig. 4 Predicted pKa of [18F]AV1451 by property prediction and comparison of analogues by literature and
predicted pKa values indicates the gamma-carboline NH of [18F]AV1451 is more acidic than a typical indole,
carbazole or azaindole
Scheme 2 Investigating the synthesis of [18F]AV1451
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from 5 to 10 min was due to the deprotection of the precursor (only 40% of N-Boc
precursor remained at 5 min) or another reason. Therefore, N-Boc precursor 1 was
first thermally deprotected to give 3, and 3 was then subjected to fluorination. Radiola-
beling was successful (Scheme 2), but only generating [18F]AV1451 2 in a modest 28%
RCC, suggesting that the non-protected precursor 3 can be radiolabeled so long as it is
solubilized. This also suggests that the modest RCC observed in the radiofluorination
of 1, and decline in further reaction after 5 min, is likely due to the decreased solubility
(and thus lower concentration) of precursor associated with thermal deprotection of
the Boc group as the reaction proceeds. The results also indicate that the benefit of N-
Boc protection in the reaction is primarily the improvement of precursor solubility.Fig. 5 HPLC traces at 1 min, 5 min and 10 min of AV1451 precursor in DMSO at 130 °C
Fig. 6 Radio-TLC (right) and -HPLC (left) data from manual [18F]AV1451 radiolabeling reactions, showing
formation of the [18F]-N-Boc-protected intermediate 4, followed by the [18F]AV1451 product 2. Aliquots
were pulled at t = 0, 1, 5, and 10 minutes and analyzed using both methods [Radio-TLC analysis was
performed using a Bioscan AR 2000 Radio-TLC scanner with EMD Millipore TLC silica gel 60 plates (3.0 cm
wide x 6.5 cm long) developed using hexane:ethyl acetate (1:1); Radio-HPLC analysis was performed using a
Shimadzu LC2010 HPLC equipped with radioactivity and UV detectors (column: Luna C18 5 micron 4.6x150
mm; MeCN:H2O gradient: 5:95 (0–3 min) – 5:95 → 95:5 (3–20 min) – 95:5 → 5:95 (20–30 min); flow rate:
1.5 mL/min; UV: 254 nm). Note: [18F]fluoride tR tended to fluctuate with the unbuffered H2O/MeCN HPLC
gradient, and is thus present at different times in the HPLC rad traces (4–11 min), while small peaks
observable in HPLC traces of t = 0 and 1 minutes are artifacts]
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[18F]AV1451 2 from nitro precursor 1 (and other reaction impurities such as 3 and 4)
in different ways. Shoup addressed the issue by adding a SPE extraction prior to HPLC
purification. The reaction mixture was diluted in water and passed through an HLB
cartridge, which removed DMSO and hydrophilic impurities, while trapping the prod-
uct and other lipophilic components. The HLB cartridge was eluted with ethanol into
the intermediate vial, which contained a low pH HPLC buffer. The removal of DMSO
and hydrophilic impurities that would otherwise complicate subsequent semi-
preparative HPLC purification allowed them to achieve separation. However, the pre-
purification process requires the commercial system to be reconfigured as extra valves
need to be added (Shoup et al. 2013). This increases operational complexity and also
the number of steps (synthesis time). On the other hand, Gao reported two different
methods to purify [18F]AV1451 (Gao et al. 2015). The first method involved using
Fe(0)/formic acid to reduce the 2-nitropyridine to the 2-aminopyridine following radi-
olabeling, similar to the approach taken in the original synthesis (Xia et al. 2013). This
requires extensive modification of a commercial synthesis system, and also increases
potential points of failure in the synthesis. The second method described by Gao is
more interesting: the reaction is quenched by addition of a 0.1 M NaHCO3 before
purification with an acidic HPLC buffer (25% MeCN, 20 mM H3PO4). While there
are not sufficient details in the report to know the extent of separation, we were in-
trigued that a simple basic quench with bicarbonate solution was sufficient to allow
purification of [18F]AV1451.
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report of the pKa of γ-carboline (Angulo et al. 1997), that the use of a basic medium was
the optimal approach to purify this radiotracer. The γ-carboline core of [18F]AV1451
contains both pyrrole-like and pyridine-like nitrogen atoms. ADMET and JChem predict
the pKa of the pyrrole NH is ~12-13, and the conjugate pKa of the pyridine is ~7-8
(Fig. 4), and so the best separation could likely be achieved at a pH where [18F]AV1451
(and other reaction components) would be neutral. Since we also wished to avoid the use
of Class 2 solvents such as MeCN, we elected to use an ethanolic phosphate buffer at
pH 9.3. This buffer will leave the pyrrole nitrogen protonated, but will not protonate the
pyridine-like nitrogen of the γ-carboline core. A comparison of the reported acidic buffers
with this basic buffer revealed sharper peaks and increased separation when using the
basic buffer (data not shown). Moreover, peak broadening and overlap of [18F]AV1451 2
with contaminants, that occurred when we used acidic HPLC mobile phases, was not an
issue with the basic buffer. The longer retention times and better peak shapes gave
baseline separation of the product from other reaction components.
Finally, with a better appreciation of the synthesis, deprotection and purification of
[18F]AV1451, we wished to automate the production of [18F]AV1451 (Scheme 1) using
a TRACERLab FXFN synthesis module. We initially re-optimized radiolabeling and
purification using a smaller amount of precursor (0.5 mg vs 1.5 mg) and solvent
(0.5 mL vs 1.5 mL), in order to further reduce HPLC peak broadening and also avoid
precipitation prior to injection onto the HPLC column. Following the concomitant
radiofluorination/Boc deprotection, the reaction mixture was purified by semi-
preparative HPLC (column: Gemini NX C18 5 micron 10x250 mm; mobile phase: 40%
Ethanol 10 mM Na2HPO4 pH: 9.3 ± 0.2; flow rate: 3 mL/min; for a typical semi-
preparative HPLC trace, see Fig. 1 ([18F]AV1451 2 tR = 21–22 min)). This semi-
preparative HPLC system showed a good retention time difference between the product
and other reaction components that allowed for routine clinical production. A subse-
quent reformulation using an Oasis HLB cartridge provided [18F]AV1451 (2). Total
synthesis time was 70 min and the method was validated for the manufacture of doses
for clinical use by completing four process-verification runs. The isolated, formulated
and non-corrected radiochemical yield (RCY) of [18F]AV1451 prepared using this
method was 202 ± 57 mCi at end-of-synthesis (EOS) (14% based on starting
[18F]fluoride), RCP = 98 ± 1%, and SA = 2521 ± 623 Ci/mmol. Doses met (or exceeded) the
QC specifications as described in the methods section (Table 1).
Conclusion
In summary, an optimized fully automated synthesis of [18F]AV1451 has been devel-
oped which uses an unmodified TRACERLab FXFN synthesis module. The synthesis
also employs no hazardous solvents, and provides radiotracer doses suitable for clinical
use. Based on our results in the development of this method, we encourage others to
utilize pKa values to help determine the optimal mobile phase to purify radiotracers
given the increasing availability of diverse HPLC stationary phases that can be used in
combination with mobile phases of varying acidity (or basicity). The use of multiple
manual reactions performed using aliquots of a batch prepared reagent (as was done
with [18F]KF/K2.2.2 in DMSO to prepare [
18F]AV1451 in this study) is also a convenient
way to quickly assess a reaction, and the role of reagents and reaction conditions.
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